Blog
RSS FeedPosted by Michael Wonder on 22 Feb 2018
NICE sticks with ‘no’ for earlier use of Halaven
22 February 2018 - Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s ...
Posted by Michael Wonder on 21 Feb 2018
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
21 February 2018 - Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care ...
Posted by Michael Wonder on 15 Feb 2018
Alternative treatments for people with thyroid cancer to be offered routinely on the NHS, says NICE
15 February 2018 - The new guidance recommends three drugs, treating two types of thyroid cancer to be made routinely available ...
Posted by Michael Wonder on 13 Feb 2018
Plaque psoriasis patients to get NHS access to Leo’s Kyntheum
13 February 2018 - Patients with severe plaque psoriasis are a step closer to getting NHS funded access to Leo ...
Posted by Michael Wonder on 12 Feb 2018
Drug company says it will negotiate terms to allow children to access new treatment for rare genetic disorder
12 February 2018 - NICE has published draft guidance that does not recommend the drug cerliponase alfa (Brineura; Biomarin) for children ...
Posted by Michael Wonder on 12 Feb 2018
NICE backs EUSA’s kidney cancer drug Fotivda
12 February 2018 - NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option ...
Posted by Michael Wonder on 12 Feb 2018
Liver cancer patients barred from NHS access to Bayer’s Stivarga
9 February 2018 - It is now looking very unlikely that patients with liver cancer will get access to Bayer’s ...
Posted by Michael Wonder on 11 Feb 2018
Roche wins UK watchdog's nod for lymphoma drug after initial snub
10 February 2018 - Britain’s healthcare watchdog recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting ...
Posted by Michael Wonder on 07 Feb 2018
Patients to benefit from myeloma treatment through CDF deal
7 February 2018 - Up to 1,600 patients with multiple myeloma could benefit from a new oral pill after NICE recommends ...
Posted by Michael Wonder on 06 Feb 2018
NICE restricts NHS use of Roche’s IPF drug Esbriet
6 February 2018 - Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the ...
Posted by Michael Wonder on 01 Feb 2018
Final NHS nod for Janssen’s Imbruvica
1 February 2018 - Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell ...
Posted by Michael Wonder on 23 Jan 2018
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
23 January 2018 - Cost regulators for NHS funded therapies in England and Wales have issued updated guidelines for the ...
Posted by Michael Wonder on 22 Jan 2018
Biogen ‘optimistic’ for NHS access to Spinraza
22 January 2018 - Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder ...
Posted by Michael Wonder on 17 Jan 2018
Pfizer asked to submit CDF proposal for Xalkori
17 January 2018 - Pfizer’s Xalkori has been turned away by NICE to treat ROS1-positive advanced non-small cell lung cancer. ...
Posted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults ...